ArticleJournal of psoriasis and psoriatic arthritis2023

Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.

Paige Kingston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.